Genmab A/S

Merck & Co.’s initial Phase II/III waveLINE-003 data for zilovertamab vedotin (zilo-V) in diffuse large B-cell lymphoma (DLBCL) at the American Society of Clinical Oncology meeting in Chicago rais

GSK could this week learn whether the European Medicines Agency will recommend pan-EU marketing authorization for Blenrep (belantamab mafodotin), its antibody-drug conjugate that was withdrawn from ma

Positive topline results from the Phase III EPCORE FL-1 trial of Genmab/AbbVie’s Epkinly (epcoritamab) in relapsed or refractory (R/R) follicular lymphoma (FL) will support submission to the US Food a

It has been a tough month for Genmab, with Johnson & Johnson opting out of a pact and a lawsuit landing from AbbVie, but the Danish biotech has come out fighting with the announcement of a new sha